In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of the announcement led to speculation that the data was not as strong as hoped.
Gilead's oncology segment is expanding, with Trodelvy and Yescarta showing potential for accelerated revenue growth. Despite risks like Medicare price caps and emerging competitors, Gilead's ...
Gilead’s Trodelvy has another string to its bow after FDA approval in patients with advanced metastatic urothelial cancer. Trodelvy (sacituzumab govitecan) has been approved for locally ...
which could have implications for Gilead's cancer drug Trodelvy. AstraZeneca reported that its TROPION-breast-01 study did not demonstrate a benefit in overall survival (OS) in patients with ...
Some results have been hidden because they may be inaccessible to you